The t (15; 17) chromosomal translocation in promyelocytic leukemia (APML, AML-M3) functions in a similar way, generating the novel fusion protein PML/RARa, and ATRA (all-trans retinoic acid) offers an effective therapy for APML by specifically suppressing oncogenic activities of the PML/RARa fusion protein [12,13]. The gene discussed is RARA; the disease is acute myeloid leukemia.